Allarity Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
ALLR$0.94-2.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
As of December 31, 2024 and 2023
(in thousands, except for share and per share data)*
| December 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash | $19,533 | $166 |
| Receivables from ATM sales | 1,416 | — |
| Other current assets | 115 | 209 |
| Prepaid expenses | 507 | 781 |
| Tax credit receivable | 770 | 815 |
| Total current assets | 22,341 | 1,971 |
| Non-current assets: | ||
| Property, plant and equipment, net | 309 | 20 |
| Intangible assets | — | 9,871 |
| Total assets | $22,650 | $11,862 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Current liabilities: | ||
| Accounts payable | $4,182 | $8,416 |
| Accrued expenses and other current liabilities | 5,232 | 1,309 |
| Warrant derivative liability | 1 | 3,083 |
| Income taxes payable | 74 | 59 |
| Convertible promissory note and accrued interest | 1,350 | 1,300 |
| Total current liabilities | 10,839 | 14,167 |
| Non-current liabilities: | ||
| Deferred tax | — | 446 |
| Total liabilities | 10,839 | 14,613 |
| Commitments and contingencies (Note 16) | ||
| Stockholders’ equity (deficit) | ||
| Series A Preferred stock, $0.0001 par value, 500,000 authorized, 20,000 designated Series A shares, 0 and 1,417 shares issued and outstanding at December 31, 2024 and 2023, respectively (liquidation preference of $17.54 at December 31, 2023) | — | 1,742 |
| Common Stock, $0.0001 par value, 250,000,000 and 750,000,000 shares authorized, at December 31, 2024 and 2023, respectively; 7,302,797 and 9,812 shares issued and outstanding at December 31, 2024 and 2023, respectively | 1 | — |
| Additional paid-in capital | 131,130 | 90,369 |
| Accumulated other comprehensive loss | (354) | (411) |
| Accumulated deficit | (118,966) | (94,451) |
| Total stockholders’ equity (deficit) | 11,811 | (2,751) |
| Total liabilities and stockholders’ equity (deficit) | $22,650 | $11,862 |
| * | All common share data has been retroactively adjusted to effect reverse stock splits in 2023 and 2024 (see Note 1). |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.